|
|
|
| Expressions and clinical significance of mutant p53 gene, DNA mismatch repair gene 1 and mismatch repair gene 2 in benign or malignant ovarian tumors tissues |
| Neijiang Hospital of Traditional Chinese Medicine, Neijiang, Sichuan Province, 641000 |
|
|
|
|
Abstract To study the expressions and clinical significance of mutant p53 gene (Mt-p53), DNA mismatch repair gene 1 (hMLH1) and mismatch repair gene 2 (hMSH2) in benign or malignant ovarian tumors. Methods: The clinical data of 95 patients with ovarian tumors from July 2017 to July 2021 were analyzed retrospectively. These patients were divided into 32 cases with benign ovarian tumor in group A, 21 cases with borderline tumor in group B and 42 cases with malignant tumor in group C according to their pathological results. The expressions of Mt-p53, hMLH1 and hMSH2 in the specimens of ovarian tumor of the patients with different pathological types, pathological features or prognosis status were analyzed and compared. The survival rate of the patients with malignant tumors within 2 years was counted. Receiver operating characteristic (ROC) curve was used to analyze the predictive efficiency of the deletions of hMLH1 and hMSH2 of the patients with malignant ovarian tumors for their prognosis. Results: The positive rate of Mt-p53 (88.1%) of the patients in group C was significantly higher than that (23.8%) of the patients in group B and that (9.4%) of the patients in group A. The positive rates of hMSH1 (66.7%) and hMSH2 (61.9%) of the patients in group C were significantly lower than those (90.5% and 90.5%) of the patients in group B and those (100.0% and 100.0%) of the patients in group A. The positive rates of hMLH1 and hMSH2 in the malignant germ cell tumors of the patients were significantly lower than those in the epithelial ovarian cancer. The positive rates of hMLH1 and hMSH2 in the moderately to highly differentiated malignant ovarian tumors of the patients were significantly higher than those in the poorly differentiated tissues, and the positive rate of Mt-p53 in the moderately to highly differentiated malignant ovarian tumors of the patients was significantly lower than that in poorly differentiated tissues. The overall survival rate of the patients with malignant tumor in 2 years was 54.8%, and the positive rate of Mt-p53 (78.3%) in the survival patients was significantly lower than that (100%) in the patients with death, and the positive rates of hMLH1 (87.0%) and hMSH2 (82.6%) in the survival patients were significantly higher than those (42.1% and 36.8%) in the patients with death (all P<0.05). There were 19 death patients with p53 gene mutation, and among them, there were 11 cases with hMLH1 gene deletion and 12 cases with hMSH2 gene deletion. ROC curve analysis showed that both the hMLH1 and the hMSH2 gene deletions of the patients with malignant ovarian tumors had the predictive efficacy for their prognosis, and the area under the curve of the hMLH1 and the hMSH2 gene deletions of the patients for their prognosis were 0.724 and 0.729 (P<0.05). Conclusion: The Mt-p53 high expression and the gene deletions of hMLH1 and hMSH2 of the patients are closely related to the occurrence and development of their malignant ovarian tumors, and the hMLH1 and hMSH2 gene deletions of the patients can also be used as the clinical indicators for predicting their prognosis.
|
|
|
|
|
|
|
|
|
